SKK
KERX

Shepherd Kaplan Krochuk’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18,766
Closed -$239K – 467
2015
Q1 		$239K Buy
18,766
+6,153
+49% +$79.1K 0.04% 264
2014
Q4 		$178K Buy
+12,613
New +$195K 0.03% 365

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Shepherd Kaplan Krochuk's KERX Position: Q2 2015 in Review

Shepherd Kaplan Krochuk sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 18,766 shares — an estimated $239K sold.

Shepherd Kaplan Krochuk first reported a position in KERX in Q4 2014 and held it in 2 quarters. The position peaked at $239K in Q1 2015. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Shepherd Kaplan Krochuk reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 18,766 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $239K.
  • Shepherd Kaplan Krochuk first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 2 quarters.
  • Shepherd Kaplan Krochuk's Keryx Biopharmaceuticals Inc position peaked at $239K in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2015, filed 14 Aug 2015.